Author: Kamle, Suchitra; Ma, Bing; He, Chuan Hua; Akosman, Bedia; Zhou, Yang; Lee, Chang Min; El-Deiry, Wafik S.; Huntington, Kelsey; Liang, Olin; Machan, Jason T.; Kang, Min-Jong; Shin, Hyeon Jun; Mizoguchi, Emiko; Lee, Chun Geun; Elias, Jack A.
Title: Chitinase 3-like-1 is a Therapeutic Target That Mediates the Effects of Aging in COVID-19 Cord-id: 6yvcsntm Document date: 2021_2_16
ID: 6yvcsntm
Snippet: COVID-19 is caused by the SARS-CoV-2 (SC2) virus and is more prevalent and severe in the elderly and patients with comorbid diseases (CM). Because chitinase 3-like-1 (CHI3L1) is induced during aging and CM, the relationships between CHI3L1 and SC2 were investigated. Here we demonstrate that CHI3L1 is a potent stimulator of the SC2 receptor ACE2 and viral spike protein priming proteases (SPP), that ACE2 and SPP are induced during aging and that anti-CHI3L1, kasugamycin and inhibitors of phosphory
Document: COVID-19 is caused by the SARS-CoV-2 (SC2) virus and is more prevalent and severe in the elderly and patients with comorbid diseases (CM). Because chitinase 3-like-1 (CHI3L1) is induced during aging and CM, the relationships between CHI3L1 and SC2 were investigated. Here we demonstrate that CHI3L1 is a potent stimulator of the SC2 receptor ACE2 and viral spike protein priming proteases (SPP), that ACE2 and SPP are induced during aging and that anti-CHI3L1, kasugamycin and inhibitors of phosphorylation, abrogate these ACE2- and SPP-inductive events. Human studies also demonstrated that the levels of circulating CHI3L1 are increased in the elderly and patients with CM where they correlate with COVID-19 severity. These studies demonstrate that CHI3L1 is a potent stimulator of ACE2 and SPP; that this induction is a major mechanism contributing to the effects of aging during SC2 infection and that CHI3L1 coopts the CHI3L1 axis to augment SC2 infection. CHI3L1 plays a critical role in the pathogenesis of and is an attractive therapeutic target in COVID-19.
Search related documents:
Co phrase search for related documents- accumulation expression and adaptive immunity: 1
- accumulation expression and lung epithelial cell: 1
- accumulation expression and lung fibroblast: 1
- accumulation expression and lung injury: 1, 2, 3, 4
- accumulation expression and lung tissue: 1, 2
- acute ali lung injury and adaptive immunity: 1
- acute ali lung injury and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31
- acute ali lung injury and lung epithelial cell: 1, 2, 3, 4, 5, 6, 7
- acute ali lung injury and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- acute ali lung injury and lung specific: 1, 2, 3, 4, 5, 6, 7
- acute ali lung injury and lung target: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute ali lung injury and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40
Co phrase search for related documents, hyperlinks ordered by date